Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Posts Earnings Results, Beats Expectations By $0.04 EPS

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) issued its quarterly earnings results on Thursday. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.04, Zacks reports. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 16.66%.

Swedish Orphan Biovitrum Price Performance

BIOVF stock opened at $49.03 on Thursday. The firm has a market cap of $17.45 billion, a price-to-earnings ratio of 163.43 and a beta of 0.35. Swedish Orphan Biovitrum has a 1-year low of $28.93 and a 1-year high of $49.03. The firm has a fifty day moving average price of $47.89 and a two-hundred day moving average price of $42.01. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.70 and a quick ratio of 0.47.

Wall Street Analyst Weigh In

Several research analysts have weighed in on BIOVF shares. Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd. HC Wainwright assumed coverage on shares of Swedish Orphan Biovitrum in a research report on Wednesday, May 6th. They set a “buy” rating on the stock. Pareto Securities lowered Swedish Orphan Biovitrum to a “hold” rating in a report on Monday, June 29th. Finally, Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.